ClinicalTrials.gov
public full text
Public Domain
Testosterone in Castration-Resistant Prostate Cancer
Primary Objective: 1\. To assess the prostate-specific antigen (PSA)-response (50% decline) to Testosterone Replacement Therapy (TRT) in men with "intermediate and good-risk" Castration-Resistant Prostate Cancer (CRPC). Secondary Objectives: 1. To assess the objective response and time-to-progression with TRT in CRPC. 2. To assess serial changes in quality of life with TRT in these CRPC subsets. 3. Translational: To study kinetics of circulating tumor cells with TRT and molecular correlates of response to TRT in CRPC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer#803905
- 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer#894090
- PRospective Prostate biOmarker Study#915327
- The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage#978822
- Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review).#1097843
Record · ID 1096407
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive